Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study


  • World
  • Tuesday, 09 Mar 2021

FILE PHOTO: A vial and sryinge are seen in front of a displayed Pfizer logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

NEW YORK (Reuters) - The COVID-19 vaccine from Pfizer Inc and BioNTech SE was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study published in the New England Journal of Medicine on Monday.

Blood taken from people who had been given the vaccine neutralized an engineered version of the virus that contained the same mutations carried on the spike portion of the highly contagious P.1 variant first identified in Brazil, the study conducted by scientists from the companies and the University of Texas Medical Branch found.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Report: AI is smarter than a person, sometimes
Venezuela opposition backs Gonzalez as presidential candidate
Ecuador president declares state of emergency over energy crisis
Restaurants are putting digital detox on the menu with smartphone-free dining
To stand out in the job market, get to grips with ChatGPT
U.S. stocks end mixed as fear index rises
Number of active drilling rigs in U.S. up this week
Huge blast at military base used by Iraqi Popular Mobilization Forces, army sources say
Three injured after chemical plant fire in U.S. Houston
North Korea conducts cruise missile warhead test on Friday, KCNA says

Others Also Read